Definium Therapeutics, Inc. (DFTX) Stock
7 of the hedge funds AlphaScala tracks reported DFTX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $79.43M. Company insiders reported 0 open-market buys and 6 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own DFTX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.69M | $79.43M | +27% |
| Marshall Wace | 1.30M | $61.10M | +8% |
| Blackstone | 562K | $26.42M | +10% |
| Point72 Steve Cohen | 484K | $22.77M | +176% |
| Duquesne Family Office Stanley Druckenmiller | 357K | $16.77M | NEW |
| D.E. Shaw David Shaw | 315K | $14.84M | +16% |
| Millennium Management Israel Englander | 266K | $12.52M | -69% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Definium Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 25, 26 | Roberts Brandi | Chief Financial Officer | SELL | 3.4K | $123K |
| Sep 25, 26 | Sullivan Mark | Chief Legal Officer | SELL | 14.1K | $514K |
| Sep 25, 26 | Wiley Matthew T. | Chief Commercial Officer | SELL | 3.1K | $113K |
| Sep 25, 26 | Barrow Robert | Chief Executive Officer | SELL | 31.6K | $1.2M |
| Sep 25, 26 | Karlin Daniel | Chief Medical Officer | SELL | 10.9K | $397K |
| Sep 3, 26 | Barrow Robert | Chief Executive Officer | SELL | 19.0K | $722K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →DFTX price chart
Powered by TradingViewWhat does Definium Therapeutics, Inc. do?
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, specializing in the development of psychedelic-derived therapeutics for psychiatric and neurological disorders. Formerly known as MindMed, it focuses on creating scientifically rigorous treatments that target root causes, such as generalized anxiety disorder (GAD), major depressive disorder (MDD), and autism spectrum disorder (ASD), aiming for long-term remission over symptom management. The company's lead candidate, DT120 orally disintegrating tablet (ODT), a proprietary lysergide (LSD) D-tartrate formulation, has FDA Breakthrough Therapy Designation for GAD and is advancing through multiple Phase 3 trials, with topline data anticipated in 2026. Additional pipeline assets include DT402, the R-enantiomer of MDMA, under investigation for ASD to improve social communication via serotonergic mechanisms. Operating in the biotechnology sector of healthcare, Definium Therapeutics employs 74 people and drives innovation in psychoplastogenic drug development to address the mental health crisis. Founded around 2019, it exemplifies precision science applied to psychedelics for scalable healing.